A vascular closure device is a tool that seals the hole left in an artery after a catheter procedure, and the newest entrant for the largest holes is Haemonetics’ PerQseal Elite, a bioabsorbable patch announced on 19 October 2026. Large-bore procedures such as transcatheter valve replacement need thick tubes passed into an artery, and closing the puncture safely is part of the operation. This explainer covers why closure matters, how a patch differs from other approaches in general terms, what Haemonetics says its device does, and what evidence readers should look for. It is not medical advice.
Vascular closure device: key takeaways
- A vascular closure device seals the artery after a catheter has been withdrawn, so that bleeding stops without long manual pressure.
- Haemonetics says PerQseal Elite is a fully bioabsorbable patch placed inside the vessel and that it covers 14F to 22F sheaths and openings up to 26F.
- The company reports 0% major complications at 30 days in the single-arm ELITE arterial study.
- The company calls the FDA decision an approval, and the release does not state the pathway.
- General explanations here are background and are labelled as such.
Why an artery needs closing
General background: when doctors reach the heart or blood vessels through a catheter, they usually enter an artery in the groin or wrist. Arteries carry blood under pressure, so after the catheter and its sheath are removed the opening must be sealed or it will bleed. For small sheaths, pressing on the site for a time is often enough. For large sheaths, pressure alone is slower and less certain, which is why dedicated closure tools exist.
What large-bore means for a vascular closure device
Sheath size is measured in French units, where each unit is one third of a millimetre. By our calculation, 14F is about 4.7 mm across, 22F is about 7.3 mm and 26F is about 8.7 mm. Haemonetics says PerQseal Elite is for procedures with 14F to 22F sheaths and can seal arteriotomies up to 26F, according to Haemonetics’ release. Those sizes are typical of structural heart procedures such as TAVR and of some endovascular repairs.
How a vascular closure device can work
This section is general and does not describe any single product. Closure tools tend to fall into a few groups. Some use sutures that are placed in the artery wall and tied or locked. Some use a plug or sealant that sits on the outside of the vessel. Others use an element, such as a patch or an anchor, that sits inside the vessel and is held against the wall. Each approach has different steps, learning curves and failure modes, and doctors choose among them based on the procedure, the anatomy and their own experience.
What Haemonetics says its patch does
According to the company, PerQseal Elite is a fully bioabsorbable patch that seals from inside the vessel and leaves nothing permanent behind. Physicians can confirm that bleeding has stopped while keeping guidewire access, and can reposition or recover the system until the implant is released. The company says the closure is sutureless and that the device has the potential to further simplify minimally invasive procedures such as TAVR. Those are claims by the manufacturer, and the release does not describe the steps in detail.
What the ELITE arterial study found
The prospective, single-arm, multicenter ELITE arterial study reported 0% major complications through 30 days under VARC-3 criteria and a mean time to hemostasis of under one minute, per the company. The text of the release does not give patient numbers. A co-investigator, Professor Nicolas van Mieghem of ZOL Hospital in Genk, Belgium, said he found the device easy to adopt and intuitive to use.
Questions to ask about any vascular closure device
This list is our suggestion. How many patients were studied, and how complex were their anatomies? Were there vascular complications such as bleeding, narrowing of the artery or leg problems, and how were they counted? How many operators took part, and how long did learning take? Was there a comparison group? What happens if the device cannot be deployed, and what back-up closure is used? How long does the absorbable material take to disappear? The release answers only some of these, and fuller data are due at the TCT conference at the end of October 2026.
Why single-arm data limit a vascular closure device claim
A single-arm study follows one group treated with the device and compares the results with expectations, not with a parallel group. It can show feasibility and a safety signal, and it is common for first approvals of devices. It cannot show superiority over other tools, because differences in patients and operators could explain the results. Readers should therefore treat the 0% figure as a starting point for comparison.
What is not disclosed
- The regulatory pathway for the U.S. decision.
- Patient numbers and the full list of endpoints.
- Pricing and the timing of the U.S. launch.
- Comparisons with other closure methods.
Risks and caveats on the vascular closure device claims
- Safety and speed figures come from the manufacturer and a single-arm study.
- Sheath-size conversions are our calculations from the standard definition.
- Any closure tool can fail, and doctors keep back-up methods.
- This is news reporting and education, not medical advice.
In our assessment, a vascular closure device for large-bore arteries is only as useful as the evidence behind it, and PerQseal Elite will be judged by the full ELITE results and by how it compares with established tools in everyday use. See also Anaesthesia Workstation Manufacturer BPL Bets Big on Medec. More in our medical device coverage, and the regulator’s general pages are at the FDA medical devices pages.
What to watch next on the vascular closure device
- Full ELITE arterial data at the TCT conference.
- Details of the U.S. labelling and pathway.
- Comparative studies and real-world registry results.
Frequently asked questions
What does a vascular closure device do?
It seals the opening in an artery after a catheter procedure so that bleeding stops.
What is special about PerQseal Elite?
The company says it is a bioabsorbable patch that seals from inside the vessel and leaves no permanent implant. See the Haemonetics company website for its description.
Is there proof it is better than other devices?
No. The reported data come from a single-arm study, which cannot show superiority.
How we reported this: we relied on the Haemonetics release of 19 October 2026 and public regulator pages. General background and our calculations are labelled. Last updated: 20 October 2026. This article is news reporting and education and not medical advice.
